The Australian Batten’s Disease (CLN-2) Therapeutics market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Batten disease (Jansky-Bielschowsky disease) is the common name for a family of severe and progressive neurological disorders (also known as neuronal ceroid lipofuscinoses – NCLs) that primarily affect children. Collectively, Batten disease is the most common inherited pediatric neurodegenerative disorder worldwide and the most common form of childhood dementia. Batten disease is a genetic disease, caused by mutations in ceroid lipofuscinosis neuronal (CLN) genes. The different types of Batten disease are classified according to the defective CLN gene that is causing the disorder (e.g., CLN1, CLN2, CLN3).
BDSRA Australia estimates that at any one time there are approximately 35 people living with a form of Batten disease in Australia, with an average of three to five new cases of Batten disease diagnosed each year in Australia.
Market Growth Drivers & Restraints
The market is expected to increase as the prevalence of neurological disorders rises, biotechnology and pharmaceutical firms engage more in R&D, the demand for new treatment methods grows, and healthcare expenditure rises.
For Batten disease, just one drug has been approved. Treatment is expensive. In rural places, there is a lack of critical services. Physical therapy market growth is being hampered by a scarcity of healthcare professionals.